Inivata conducted two prospective, multi-center studies in collaboration with 41 key institutions across the United States. The data, published in JCO Precision Oncology, highlights the potential of Inivata’s first Medicare-reimbursed commercial test to improve delivery of comprehensive tumor genomic profiling.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
